US 12,233,091 B2
Vaccine compositions and methods
Michael Har-Noy, Jerusalem (IL)
Assigned to Mirror Biologics, Inc., Wesley Chapel, FL (US)
Filed by Mirror Biologics, Inc., Mesa, AZ (US)
Filed on Apr. 29, 2020, as Appl. No. 16/862,069.
Application 16/862,069 is a division of application No. 16/215,116, filed on Dec. 10, 2018, granted, now 10,751,372.
Application 16/215,116 is a continuation of application No. 12/434,168, filed on May 1, 2009, abandoned.
Claims priority of provisional application 61/050,294, filed on May 5, 2008.
Claims priority of provisional application 61/049,990, filed on May 2, 2008.
Prior Publication US 2020/0261509 A1, Aug. 20, 2020
Int. Cl. A61K 35/28 (2015.01); A61K 35/12 (2015.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); C12N 5/0783 (2010.01)
CPC A61K 35/28 (2013.01) [A61K 39/39 (2013.01); A61K 39/4611 (2023.05); A61K 39/464476 (2023.05); C12N 5/0636 (2013.01); A61K 2035/124 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); C12N 2501/51 (2013.01); C12N 2501/515 (2013.01); C12N 2501/52 (2013.01)] 14 Claims
 
1. A method of reducing antigens from a tumor in a host comprising:
administering a pharmaceutical composition comprising an adjuvant and one or more antigens,
wherein the source of one or more antigens is chaperone rich cell lysates (CRCL), wherein the source of the CRCL is the tumor and the CRCL comprises multiple chaperone complexes enriched by free solution-isoelectric focusing, the multiple chaperone complexes comprising GRP94/gp96, HSP90, HOSP70 and calreticulin,
wherein the adjuvant comprises living immune cells, wherein the immune cells comprise activated T-cells that are allogeneic to the host, the T-cells comprising memory Th1 cells activated by cross-linking CD3 and CD28 surface molecules, and
wherein the pharmaceutical composition, upon administration to the host, stimulates a Th1 immune response in the host to the one or more antigens in the composition, thereby stimulating a Th1 immune response in the host against the antigens from the tumor.